

Jean-Philippe Collet

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8976593/publications.pdf>

Version: 2024-02-01

105
papers

27,730
citations

76326

40
h-index

28297

105
g-index

109
all docs

109
docs citations

109
times ranked

21657
citing authors

#	ARTICLE	IF	CITATIONS
1	Severe Libman-â€“Sacks endocarditis complicating antiphospholipid syndrome: a retrospective analysis of 23 operated cases. <i>Rheumatology</i> , 2023, 62, 707-715.	1.9	4
2	Resumption of Antiplatelet Therapy after Major Bleeding. <i>Thrombosis and Haemostasis</i> , 2023, 123, 135-149.	3.4	4
3	2021 ESC/EACTS Guidelines for the management of valvular heart disease. <i>European Heart Journal</i> , 2022, 43, 561-632.	2.2	2,169
4	Cusp-Overlapping Projections in TAVR. <i>JACC: Cardiovascular Interventions</i> , 2022, 15, 162-164.	2.9	6
5	European Society of Cardiology guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 1-â€“epidemiology, pathophysiology, and diagnosis. <i>Cardiovascular Research</i> , 2022, 118, 1385-1412.	3.8	27
6	The new European Society of Cardiology/European Association for Cardio-Thoracic Surgery recommendations for transcatheter aortic valve intervention are too restrictive. <i>European Heart Journal</i> , 2022, 43, 2751-2752.	2.2	4
7	ESC/EAS guidelines for the detection, prevention, and treatment of individuals at risk of a first myocardial infarction: effect of 5 years of updates and the new SCORE2. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 8, 633-643.	3.0	8
8	Timing of invasive management of NSTEMI-ACS: is the time up for early management?. <i>European Heart Journal</i> , 2022, 43, 3161-3163.	2.2	2
9	Antithrombotic Therapy Following Transcatheter Aortic Valve Replacement. <i>Journal of Clinical Medicine</i> , 2022, 11, 2190.	2.4	3
10	Apixaban vs. standard of care after transcatheter aortic valve implantation: the ATLANTIS trial. <i>European Heart Journal</i> , 2022, 43, 2783-2797.	2.2	74
11	Evolution of TAVI patients and techniques over the past decade: The French TAVI registries. <i>Archives of Cardiovascular Diseases</i> , 2022, 115, 206-213.	1.6	9
12	2019 ESC/EAS Guidelines for management of dyslipidaemia: strengths and limitations. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021, 7, 324-333.	3.0	22
13	Lesson learnt from the new 2020 ESC guidelines on non-ST-segment elevation acute coronary syndrome: when clinical judgement precedes and overpasses weak recommendations. 2020 non-ST-segment elevation acute coronary syndrome guidelines on pre-treatment: primum non nocere!. <i>European Heart Journal</i> , 2021, 42, 2607-2608.	2.2	10
14	Indirect comparison of the efficacy and safety of alirocumab and evolocumab: a systematic review and network meta-analysis. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021, 7, 225-235.	3.0	40
15	Life-threatening and major cardiac events during long-distance races: updates from the prospective RACE PARIS registry with a systematic review and meta-analysis. <i>European Journal of Preventive Cardiology</i> , 2021, 28, 679-686.	1.8	12
16	Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation and coexistent atrial fibrillation -â€“ Dual versus triple antithrombotic therapy. <i>European Heart Journal</i> , 2021, 42, 2020-2021.	2.2	172
17	Double vs. triple antithrombotic therapy in atrial fibrillation patients undergoing percutaneous coronary intervention: does clinical presentation matter?. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021, 7, f61-f62.	3.0	1
18	Optimal timing of invasive angiography in non-ST-segment elevation acute coronary syndromes-â€“do we need more data?. <i>European Heart Journal</i> , 2021, 42, 353-354.	2.2	4

#	ARTICLE	IF	CITATIONS
19	Prasugrel over ticagrelor in non-ST-elevation acute coronary syndromes: is it justified?. <i>European Heart Journal</i> , 2021, 42, 2611-2612.	2.2	1
20	2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. <i>European Heart Journal</i> , 2021, 42, 1289-1367.	2.2	3,048
21	Questions and answers on antithrombotic therapy and revascularization strategies in non-ST-elevation acute coronary syndrome (NSTEMI-ACS): a companion document of the 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. <i>European Heart Journal</i> , 2021, 42, 1368-1378.	2.2	33
22	Questions and answers on workup diagnosis and risk stratification: a companion document of the 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. <i>European Heart Journal</i> , 2021, 42, 1379-1386.	2.2	11
23	Antithrombotic Therapy in Acute Coronary Syndromes: Current Evidence and Ongoing Issues Regarding Early and Late Management. <i>Thrombosis and Haemostasis</i> , 2021, 121, 854-866.	3.4	8
24	Single Versus Dual Antiplatelet Therapy Following TAVR. <i>JACC: Cardiovascular Interventions</i> , 2021, 14, 234-236.	2.9	9
25	Transcatheter aortic valve thrombosis: Data from a French multicenter cohort analysis. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 98, 352-362.	1.7	2
26	Management of antithrombotic therapy in patients undergoing transcatheter aortic valve implantation: a consensus document of the ESC Working Group on Thrombosis and the European Association of Percutaneous Cardiovascular Interventions (EAPCI), in collaboration with the ESC Council on Valvular Heart Disease. <i>European Heart Journal</i> , 2021, 42, 2265-2269.	2.2	81
27	Inappropriate Use of Oral Antithrombotic Combinations in an Outpatient Setting and Associated Risks: A French Nationwide Cohort Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 2367.	2.4	1
28	Bleeding in the Elderly: Risk Factors and Impact on Clinical Outcomes After an Acute Coronary Syndrome, a Sub-study of the Randomized ANTARCTIC Trial. <i>American Journal of Cardiovascular Drugs</i> , 2021, 21, 681-691.	2.2	4
29	Antithrombotic therapies in aortic and peripheral arterial diseases in 2021: a consensus document from the ESC working group on aorta and peripheral vascular diseases, the ESC working group on thrombosis, and the ESC working group on cardiovascular pharmacotherapy. <i>European Heart Journal</i> , 2021, 42, 4013-4024.	2.2	76
30	Antithrombotic Therapy After Transcatheter Aortic Valve Replacement. <i>JACC: Cardiovascular Interventions</i> , 2021, 14, 1688-1703.	2.9	31
31	Major bleeding and the ADP-binding enzyme creatine kinase in non-ST-segment elevation acute coronary syndromes. <i>European Heart Journal</i> , 2021, 42, 2313-2314.	2.2	1
32	Would Anyone Dare Abandon Repositioning of Self-Expanding TAVR?. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 1825-1827.	2.9	1
33	Diagnosis and Management of Acute Coronary Syndrome: What is New and Why? Insight From the 2020 European Society of Cardiology Guidelines. <i>Journal of Clinical Medicine</i> , 2020, 9, 3474.	2.4	15
34	The "Ten Commandments"™ for the 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. <i>European Heart Journal</i> , 2020, 41, 3495-3497.	2.2	283
35	TAVR. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 2667-2669.	2.9	3
36	Prevention of thrombotic risk in hospitalized patients with COVID-19 and hemostasis monitoring. <i>Critical Care</i> , 2020, 24, 364.	5.8	118

#	ARTICLE	IF	CITATIONS
37	Early Aspirin Discontinuation Following Acute Coronary Syndrome or Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. <i>Journal of Clinical Medicine</i> , 2020, 9, 680.	2.4	9
38	Effect of oral anticoagulation on clinical outcomes and haemodynamic variables after successful transcatheter aortic valve implantation. <i>Archives of Cardiovascular Diseases</i> , 2020, 113, 341-349.	1.6	5
39	Antithrombotic Therapy for Patients With Left Ventricular Mural Thrombus. <i>Journal of the American College of Cardiology</i> , 2020, 75, 1676-1685.	2.8	124
40	Intracardiac cement embolism during percutaneous vertebroplasty: incidence, risk factors and clinical management. <i>European Radiology</i> , 2019, 29, 663-673.	4.5	53
41	2018 ESC/EACTS Guidelines on myocardial revascularization. <i>European Heart Journal</i> , 2019, 40, 87-165.	2.2	4,537
42	Updated Expert Consensus Statement on Platelet Function and Genetic Testing for Guiding P2Y12 Receptor Inhibitor Treatment in Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 1521-1537.	2.9	366
43	Reasons for the Failure of Platelet Function Testing to Adjust Antiplatelet Therapy. <i>Circulation: Cardiovascular Interventions</i> , 2019, 12, e007749.	3.9	2
44	Aspirin-Free Strategies After PCI. <i>Journal of the American College of Cardiology</i> , 2019, 74, 2028-2031.	2.8	3
45	Antithrombotic therapy in patients undergoing transcatheter aortic valve implantation. <i>Heart</i> , 2019, 105, 742-748.	2.9	27
46	Elderly Patients with ST-Segment Elevation Myocardial Infarction: A Patient-Centered Approach. <i>Drugs and Aging</i> , 2019, 36, 531-539.	2.7	16
47	Interval From Initiation of Prasugrel to Coronary Angiography in Patients With Non-ST-Segment Elevation Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2019, 73, 906-914.	2.8	14
48	A prescription support-tool for chronic management of oral antithrombotic combinations in adults based on a systematic review of international guidelines. <i>PLoS ONE</i> , 2019, 14, e0211695.	2.5	6
49	Incidence of, risk factors for and impact of readmission for heart failure after successful transcatheter aortic valve implantation. <i>Archives of Cardiovascular Diseases</i> , 2019, 112, 765-772.	1.6	18
50	Impact of a Prescription Support Tool to Improve Adherence to the Guidelines for the Prescription of Oral Antithrombotics: The Combi-AT Randomized Controlled Trial Using Clinical Vignettes. <i>Journal of Clinical Medicine</i> , 2019, 8, 1919.	2.4	3
51	The Tricuspid Valve. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 2496-2498.	2.9	4
52	Copeptin as a prognostic biomarker in acute myocardial infarction. <i>International Journal of Cardiology</i> , 2019, 274, 337-341.	1.7	19
53	Long-Term Mortality and Early Valve Dysfunction According to Anticoagulation Use. <i>Journal of the American College of Cardiology</i> , 2019, 73, 13-21.	2.8	85
54	Antithrombotic Therapy After Transcatheter Aortic Valve Replacement. <i>Circulation: Cardiovascular Interventions</i> , 2019, 12, e007411.	3.9	55

#	ARTICLE	IF	CITATIONS
55	Antithrombotic therapy and body mass: an expert position paper of the ESC Working Group on Thrombosis. <i>European Heart Journal</i> , 2018, 39, 1672-1686f.	2.2	106
56	Management of antiplatelet therapy in patients undergoing elective invasive procedures: Proposals from the French Working Group on perioperative hemostasis (GIHP) and the French Study Group on thrombosis and hemostasis (GFHT). In collaboration with the French Society for Anesthesia and Intensive Care (SFAR). <i>Archives of Cardiovascular Diseases</i> , 2018, 111, 210-223.	1.6	22
57	Periprocedural myocardial infarction and injury in elective coronary stenting. <i>European Heart Journal</i> , 2018, 39, 1100-1109.	2.2	136
58	Anticoagulation in Acute Coronary Syndrome-State of the Art. <i>Progress in Cardiovascular Diseases</i> , 2018, 60, 508-513.	3.1	14
59	Management of antiplatelet therapy in patients undergoing elective invasive procedures. Proposals from the French Working Group on perioperative haemostasis (GIHP) and the French Study Group on thrombosis and haemostasis (GFHT). In collaboration with the French Society for Anaesthesia and Intensive Care Medicine (SFAR). <i>Anaesthesia, Critical Care & Pain Medicine</i> . 2018, 37, 379-389.	1.4	25
60	Oral anti-Xa anticoagulation after trans-aortic valve implantation for aortic stenosis: The randomized ATLANTIS trial. <i>American Heart Journal</i> , 2018, 200, 44-50.	2.7	111
61	2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS). <i>European Heart Journal</i> , 2018, 39, 763-816.	2.2	2,305
62	2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. <i>European Heart Journal</i> , 2018, 39, 213-260.	2.2	2,246
63	Aspirin-free strategies in cardiovascular disease and cardioembolic stroke prevention. <i>Nature Reviews Cardiology</i> , 2018, 15, 480-496.	13.7	180
64	Management of antithrombotic therapy after bleeding in patients with coronary artery disease and/or atrial fibrillation: expert consensus paper of the European Society of Cardiology Working Group on Thrombosis. <i>European Heart Journal</i> , 2017, 38, ehw454.	2.2	86
65	Intravenous Enoxaparin Versus Unfractionated Heparin in Elderly Patients Undergoing Primary Percutaneous Coronary Intervention. <i>Angiology</i> , 2017, 68, 29-39.	1.8	10
66	Respective role of surface electrocardiogram and His bundle recordings to assess the risk of atrioventricular block after transcatheter aortic valve replacement. <i>International Journal of Cardiology</i> , 2017, 236, 216-220.	1.7	22
67	Thrombus composition in sudden cardiac death from acute myocardial infarction. <i>Resuscitation</i> , 2017, 113, 108-114.	3.0	24
68	Effect of intracoronary administration of AAV1/SERCA2a on ventricular remodelling in patients with advanced systolic heart failure: results from the AGENTâ€HF randomized phase 2 trial. <i>European Journal of Heart Failure</i> , 2017, 19, 1534-1541.	7.1	75
69	Adverse events while awaiting myocardial revascularization: a systematic review and meta-analysis. <i>European Journal of Cardio-thoracic Surgery</i> , 2017, 52, 206-217.	1.4	39
70	P5559The effect of prehospital P2Y12 receptor inhibition in primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: the ATLANTIC-Elderly analysis. <i>European Heart Journal</i> , 2017, 38, .	2.2	0
71	Intravenous enoxaparin anticoagulation in percutaneous left atrial cardiac procedures. <i>EuroIntervention</i> , 2017, 13, 1226-1233.	3.2	7
72	Exome sequencing of extreme clopidogrel response phenotypes identifies <i>B4GALT2</i> as a determinant of on-treatment platelet reactivity. <i>Clinical Pharmacology and Therapeutics</i> , 2016, 100, 287-294.	4.7	22

#	ARTICLE	IF	CITATIONS
73	Switching between thienopyridines in patients with acute myocardial infarction and quality of care. <i>Open Heart</i> , 2016, 3, e000384.	2.3	9
74	Individualized Modeling Approach for ADAPT Duration. <i>Journal of the American College of Cardiology</i> , 2016, 67, 2235-2236.	2.8	0
75	Platelet function monitoring to adjust antiplatelet therapy in elderly patients stented for an acute coronary syndrome (ANTARCTIC): an open-label, blinded-endpoint, randomised controlled superiority trial. <i>Lancet, The</i> , 2016, 388, 2015-2022.	13.7	303
76	The Triple Challenge of Triple Therapy. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 1703-1705.	2.9	1
77	Registry on acute cardiovascular events during endurance running races: the prospective RACE Paris registry. <i>European Heart Journal</i> , 2016, 37, 2531-2541.	2.2	30
78	Intravenous Clopidogrel (MDCO-157) Compared with Oral Clopidogrel: The Randomized Cross-Over AMPHORE Study. <i>American Journal of Cardiovascular Drugs</i> , 2016, 16, 43-53.	2.2	4
79	2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. <i>European Heart Journal</i> , 2016, 37, 267-315.	2.2	5,890
80	Platelet Function Test-Guided Strategy. <i>Circulation: Cardiovascular Interventions</i> , 2015, 8, e002716.	3.9	1
81	Efficacy of Ex Vivo Autologous and In Vivo Platelet Transfusion in the Reversal of P2Y ₁₂ Inhibition by Clopidogrel, Prasugrel, and Ticagrelor. <i>Circulation: Cardiovascular Interventions</i> , 2015, 8, e002786.	3.9	59
82	Antithrombotic therapy in the elderly: expert position paper of the European Society of Cardiology Working Group on Thrombosis. <i>European Heart Journal</i> , 2015, 36, ehv304.	2.2	175
83	Platelet effect of prasugrel and ticagrelor in patients with ST-segment elevation myocardial infarction. <i>Archives of Cardiovascular Diseases</i> , 2015, 108, 502-510.	1.6	8
84	Sex-related differences after contemporary primary percutaneous coronary intervention for ST-segment elevation myocardial infarction. <i>Archives of Cardiovascular Diseases</i> , 2015, 108, 428-436.	1.6	17
85	Incidence and consequence of major bleeding in primary percutaneous intervention for ST-elevation myocardial infarction in the era of radial access: an analysis of the international randomized Acute myocardial infarction Treated with primary angioplasty and intravenous enoxaparin Or unfractionated heparin to Lower ischemic and bleeding events at short- and Long-term follow-up trial. <i>American Heart Journal</i> , 2015, 170, 778-786.	2.7	9
86	Dual antiplatelet therapy: optimal timing, management, and duration. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2015, 1, 198-204.	3.0	32
87	Genetic and platelet function testing of antiplatelet therapy for percutaneous coronary intervention: the ARCTIC-GENE study. <i>European Journal of Clinical Pharmacology</i> , 2015, 71, 1315-1324.	1.9	31
88	Reappraisal of thienopyridine pretreatment in patients with non-ST elevation acute coronary syndrome: a systematic review and meta-analysis. <i>BMJ, The</i> , 2014, 347, g6269-g6269.	6.0	75
89	Effect of Prasugrel Pre-Treatment Strategy in Patients Undergoing Percutaneous Coronary Intervention for NSTEMI. <i>Journal of the American College of Cardiology</i> , 2014, 64, 2563-2571.	2.8	64
90	Pretreatment with P2Y ₁₂ Inhibitors in Non-ST-Segment Elevation Acute Coronary Syndrome: An Outdated and Harmful Strategy. <i>Circulation</i> , 2014, 130, 1904-1914.	1.6	36

#	ARTICLE	IF	CITATIONS
91	Prehospital Ticagrelor in ST-Segment Elevation Myocardial Infarction. <i>New England Journal of Medicine</i> , 2014, 371, 1016-1027.	27.0	538
92	Coronary Revascularization in the Diabetic Patient. <i>Circulation</i> , 2014, 130, 918-922.	1.6	19
93	Dual-antiplatelet treatment beyond 1 year after drug-eluting stent implantation (ARCTIC-Interruption): a randomised trial. <i>Lancet</i> , The, 2014, 384, 1577-1585.	13.7	269
94	Prasugrel but not high dose clopidogrel overcomes the lansoprazole neutralizing effect of P2Y12 inhibition: Results of the randomized DOSAPI study. <i>European Journal of Clinical Pharmacology</i> , 2014, 70, 1049-1057.	1.9	9
95	Impact of Red Blood Cell Transfusion on Platelet Aggregation and Inflammatory Response in Anemic Coronary and Noncoronary Patients. <i>Journal of the American College of Cardiology</i> , 2014, 63, 1289-1296.	2.8	78
96	Pretreatment with P2Y12 inhibitors in non-ST-segment elevation acute coronary syndrome: Time to revise the guidelines?. <i>Archives of Cardiovascular Diseases</i> , 2014, 107, 1-3.	1.6	1
97	Expert position paper on the management of antiplatelet therapy in patients undergoing coronary artery bypass graft surgery. <i>European Heart Journal</i> , 2014, 35, 1510-1514.	2.2	70
98	A Direct Comparison of Intravenous Enoxaparin With Unfractionated Heparin in Primary Percutaneous Coronary Intervention (from the ATOLL Trial). <i>American Journal of Cardiology</i> , 2013, 112, 1367-1372.	1.6	54
99	Efficacy and safety of enoxaparin versus unfractionated heparin during percutaneous coronary intervention: systematic review and meta-analysis. <i>BMJ: British Medical Journal</i> , 2012, 344, e553-e553.	2.3	159
100	High on-thienopyridine platelet reactivity in elderly coronary patients: the SENIOR-PLATELET study. <i>European Heart Journal</i> , 2012, 33, 1241-1249.	2.2	127
101	Bedside Monitoring to Adjust Antiplatelet Therapy for Coronary Stenting. <i>New England Journal of Medicine</i> , 2012, 367, 2100-2109.	27.0	788
102	Composition of Coronary Thrombus in Acute Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2011, 57, 1359-1367.	2.8	329
103	Cardiovascular Risk in Clopidogrel-Treated Patients According to Cytochrome P450 2C19*2 Loss-of-Function Allele or Proton Pump Inhibitor Coadministration. <i>Journal of the American College of Cardiology</i> , 2010, 56, 134-143.	2.8	348
104	Immediate vs Delayed Intervention for Acute Coronary Syndromes. <i>JAMA - Journal of the American Medical Association</i> , 2009, 302, 947.	7.4	255
105	Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. <i>Lancet</i> , The, 2009, 373, 309-317.	13.7	864